If you have been reading about heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-05. Numbers and descriptions here follow the published literature rather than marketing material.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | Reversed-phase HPLC with UV detection | Separates target peptide from truncated and oxidised forms |
| Identity confirmation | LC-MS or ESI-MS | Compares observed and calculated molecular ion |
| Primary degradation route | Methionine oxidation | Forms the sulfoxide; monitored as an early-eluting peak |
| Short-term storage | 2 to 8 degrees Celsius | Applies to working vials and reconstituted portions |
| Common synonyms | ACTH(4–10) analogue, MEHFPGP | Descriptive names used in laboratory catalogues |
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
As long as the artery enlarges sufficiently to compensate for the extra thickness of the atheroma, then no narrowing ("stenosis") of the opening ("lumen") occurs. The artery expands with an egg-shaped cross-section, still with a circular opening. If the enlargement is beyond proportion to the atheroma thickness, then an aneurysm is created.
=== Keratin-like characteristics === Spongin also exhibits compositional similarities to keratin, particularly in its sulfur content and thermal stability. It withstands temperatures up to 300 °C, which is more characteristic for keratin than collagen. However, due to spongin's distinct biochemical features, its full molecular classification remains unknown.
In the fields of geometry and biochemistry, a triple helix (pl.: triple helices) is a set of three congruent geometrical helices with the same axis, differing by a translation along the axis. This means that each of the helices keeps the same distance from the central axis. As with a single helix, a triple helix may be characterized by its pitch, diameter, and handedness. Examples of triple helices include triplex DNA, triplex RNA, the collagen helix, and collagen-like proteins.
The fissile properties of uranium-233 were established at the University of California, Berkeley during 1941 and early 1942 by Glenn T. Seaborg, John W. Gofman and Raymond W. Stoughton, who showed that the isotope undergoes fission with slow neutrons and was therefore a potential nuclear fuel. Their report was mailed to the Uranium Committee in Washington on 14 April 1942, but wartime secrecy kept the work from open publication until 1947, when an abridged version appeared in Physical Review. In 1946, the public first became informed of uranium-233 bred from thorium as "a third available source of nuclear energy and atom bombs" (in addition to uranium-235 and plutonium-239), following a United Nations report and a speech by Glenn T. Seaborg. The United States produced, over the course of the Cold War, approximately 2 metric tons of uranium-233, in varying levels of chemical and isotopic purity. These were produced at the Hanford Site and Savannah River Site in reactors that were designed for the production of plutonium-239.
Sources: en.wikipedia.org
== Application == Microtox has a variety of environmental and industrial applications. Common applications are for testing the toxicity of both marine and freshwater, as well as sediments for pesticides and other inorganic and organic chemicals. Drinking water: Microtox is used to test drinking water sources in many areas where either accidental or deliberate contamination is possible. Toxic contaminants in drinking water are indicated by a change in the color or intensity of light, or by a change in the rate of oxygen use. Lakes and rivers: Microtox is used to test the toxicity of lake and river sediments contaminated by metals or nonspecific contaminants. The Solid-Phase test is used for sediments, while either the Basic test or the 100% test is used for pore water. Sediment testing: Microtox is used to test and evaluate the toxicity of various marine and freshwater sediments contaminated by metals and organics. Aqueous extracts of contaminated soils, drilling muds, and sludge. Microtox data may be used to establish apparent effects threshold (AET), sediment quality standards and used for NPDES permits, as well as Superfund cleanup levels. Industrial: This bioassay is used in the assessment of the toxicity of complex industrial effluent sources. It is a cost-effective way for monitoring and testing large numbers of samples. Microtox can also be applied as an early warning system (EWS) and aid in detecting the presence of toxic materials, as well as predict the outcomes of other bioassays and tests.
Pulmonary arterial hypertension (PAH) is a syndrome in which the blood pressure in the pulmonary arteries and pulmonary arterioles (the blood vessels located proximal to the capillary bed, the site of oxygen exchange in the lungs) is elevated. This pre-capillary pulmonary artery pressure being elevated is essential, and by definition a mean pulmonary artery pressure greater than 20 mmHg as measured by a right heart catheterization is required for the diagnosis. This pre-capillary pulmonary hypertension is confirmed with measuring pulmonary vascular resistance being greater than 3 Woods Units. A pulmonary artery wedge pressure being less than 15 mmHg (also measured by right heart catheterization) excludes post-capillary bed (in the veins distal to the capillary bed) pulmonary hypertension. Pulmonary arterial hypertension is a subgroup of pulmonary hypertension and is categorized as World Health Organization as group 1. PAH is further subdivided into various categories based on the cause, including idiopathic, heritable, drug and toxin induced, PAH associated with specific diseases (such as connective tissue disorders, portal hypertension or HIV), PAH that is responsive to vasodilators, PAH with venous or capillary involvement, and persistent PAH in the newborn period. If left untreated, the increased pulmonary vascular resistance will eventually lead to right heart failure and death. In the 1980s (before disease specific treatments became available) the 5 year survival rate was 34%.
Difficulty with walking Tingling or loss of sensation (numbness) in hands and feet Loss of tendon reflexes Loss of muscle function or paralysis of the lower legs Mental confusion/speech difficulties Pain Involuntary eye movements (nystagmus) Vomiting A selective impairment of the large proprioceptive sensory fibers without motor impairment can occur and present as a prominent sensory ataxia, which is a loss of balance and coordination due to loss of the proprioceptive inputs from the periphery and loss of position sense.
Sources: en.wikipedia.org
=== Brand names === Janssen's patent on risperidone expired in December 2003, opening the market for cheaper generic versions from other companies, and Janssen's exclusive marketing rights expired in June 2004 (the result of a pediatric extension). It is available under many brand names worldwide. Risperidone is available as a tablet, an oral solution, and an ampule, which is a depot injection. Brand names include Risperdal, Risperdal Consta, Risperdal M-Tab, Risperdal Quicklets, Risperlet, Okedi, and Perseris.
=== Approval of discoveries === In December 2015, the conclusions of a new JWP report were published by IUPAC in a press release, in which element 113 was awarded to Riken; elements 115, 117, and 118 were awarded to the collaborations involving the JINR. A joint 2016 announcement by IUPAC and IUPAP had been scheduled to coincide with the publication of the JWP reports, but IUPAC alone decided on an early release because the news of Riken being awarded credit for element 113 had been leaked to Japanese newspapers. For the first time in history, a team of Asian physicists would name a new element. The JINR considered the awarding of element 113 to Riken unexpected, citing their own 2003 production of elements 115 and 113, and pointing to the precedents of elements 103, 104, and 105 where IUPAC had awarded joint credit to the JINR and LBNL. They stated that they respected IUPAC's decision, but reserved determination of their position for the official publication of the JWP reports. The full JWP reports were published on 21 January 2016. The JWP recognised the discovery of element 113, assigning priority to Riken. They noted that while the individual decay energies of each nuclide in the decay chain of 278113 were inconsistent, their sum was now confirmed to be consistent, strongly suggesting that the initial and final states in 278113 and its daughter 262Db were the same for all three events. The decay of 262Db to 258Lr and 254Md was previously known, firmly anchoring the decay chain of 278113 to known regions of the chart of nuclides.
Until the second half of the 18th century, watches were luxury items; as an indication of how highly they were valued, English newspapers of the 18th century often include advertisements offering rewards of between one and five guineas merely for information that might lead to the recovery of stolen watches. By the end of the 18th century, however, watches (while still largely hand-made) were becoming more common; special cheap watches were made for sale to sailors, with crude but colorful paintings of maritime scenes on the dials. Up to the 1720s, almost all watch movements were based on the verge escapement, which had been developed for large public clocks in the 14th century. This type of escapement involved a high degree of friction and did not include any kind of jewelling to protect the contacting surfaces from wear. As a result, a verge watch could rarely achieve any high standard of accuracy. The first widely used improvement was the cylinder escapement, developed by the Abbé de Hautefeuille early in the 18th century and applied by the English maker George Graham. Then, towards the end of the 18th century, the lever escapement (invented by Thomas Mudge in 1755) was put into limited production by a handful of makers including Josiah Emery (a Swiss based in London) and Abraham-Louis Breguet. With this, a domestic watch could keep time to within a minute a day. Lever watches became common after about 1820, and this type is still used in most mechanical watches.
Sources: en.wikipedia.org
Dry powder is usually kept at about -20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for short working periods. Containers should stay sealed and protected from light and moisture to limit degradation.
Oxidation of the methionine residue to the sulfoxide is a frequently reported change, and it usually appears as an earlier-eluting peak in reversed-phase chromatography. Backbone hydrolysis products can also accumulate in aqueous solution.
Liquid chromatography coupled with mass spectrometry is the usual approach, because the observed molecular ion can be compared with a calculated mass of about 813.9 Da. Retention time alone does not establish identity.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.